Heidelberg Pharma

Update in progress

HPHA.DE (XETRA)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Heidelberg Pharma AG is a Germany‑based biopharma focused on oncology and antibody–amanitin conjugates (ATAC). Key programs include HDP‑101, an anti‑BCMA antibody in Phase I/IIa for relapsed/refractory multiple myeloma; HDP‑102 (preclinical) for non‑Hodgkin lymphoma; HDP‑103 for metastatic castration‑resistant prostate cancer; HDP‑104 for GI tumors; HDP‑201 for colorectal cancer; TAK‑ATAC for oncology. TLX250‑CDx for kidney cancer (Phase III) and TLX250/girentuximab (Phase II). RHB‑107 for COVID‑19 (Phase II). Licensing with Huadong Medicine for Asia. Formerly Wilex, renamed 2017; founded 1997; based in Ladenburg.

Company score

Sentiment: -0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.16; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive